Emerald Health Therapeutics Inc.'s short form base shelf prospectus dated March 13, 2019, was filed with and accepted by the TSX Venture Exchange, and filed with and receipted by the British Columbia Securities Commission, pursuant to the provisions of the Securities Act (British Columbia), and the Ontario Securities Commission, pursuant to the provisions of the Securities Act (Ontario), on March 14, 2019. The prospectus was also filed under Multilateral Instrument 11-102, Passport System, in Alberta, Saskatchewan, Manitoba, Quebec, New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador. A receipt for the prospectus is deemed to be issued by the regulators in each of those jurisdictions, if the conditions of the instrument have been satisfied.

The TSX Venture Exchange has accepted for filing documentation with respect to an offering of 4,385,965 units of the company at a price of 57 cents per unit for total gross proceeds of $2.5-million. The offering was made pursuant to a prospectus supplement dated Nov. 15, 2019, to the company's short form base shelf prospectus dated March 13, 2019, which prospectus supplement was amended by the amendment to the prospectus supplement dated Nov. 28, 2019.

The TSX Venture Exchange has been advised that closing of the offering occurred on Nov. 29, 2019, for gross proceeds of $2.5-million.

Agents:  none

Offering:  4,385,965 units (Each unit consists of one share and one common share purchase warrant.)

Unit price:  57 cents per unit

Warrant exercise price/term:  75 cents per share to Nov. 29, 2024 (In the event that the closing price of the common shares of the company on the TSX Venture Exchange or such other principal exchange on which the common shares are then trading is greater than $1.50 per share for a period of 10 consecutive trading days at any time after the closing of the offering, the company may accelerate the expiry date of the warrants by giving written notice to the purchaser and, in such case, the warrants will expire on the 15th day after the date on which such notice is given by the company.)

Agents' warrants:  none

Greenshoe option:  none

For further information, please refer to the company's short form base shelf prospectus dated March 13, 2019, the prospectus supplement dated Nov. 15, 2019, and the amendment to the prospectus supplement dated Nov. 28, 2019, which are available under the company's SEDAR profile, and the company's news releases dated Nov. 13, 2019, and Nov. 29, 2019, which are available under the company's SEDAR profile.